Chen Jiashu, Yang Wei, Ying Zesheng, Yang Ping, Liang Yuting, Liang Chen, Shang Baojin, Zhang Hong, Cai Yingjie, Peng Xiaojiao, Sun Hailang, Ma Wenping, Ge Ming
Department of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Image Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Children (Basel). 2025 Mar 20;12(3):387. doi: 10.3390/children12030387.
Medulloblastoma (MB) represents the predominant intracranial neoplasm observed in pediatric populations, characterized by a five-year survival rate ranging from 60% to 80%. Anticipating the prognostic outcome of medulloblastoma in children prior to surgical intervention holds paramount significance for informing treatment modalities effectively. Radiomics has emerged as a pervasive tool in both prognostic anticipation and therapeutic management across diverse tumor spectra. This study aims to develop a radiomics-based prediction model for the prognosis of children with MB and to validate the contribution of radiomic features in predicting the prognosis of MB when combined with clinical features.
Patients diagnosed with medulloblastoma at our hospital from December 2012 to March 2022 were randomly divided into a training cohort ( = 40) and a test cohort ( = 41). Regions of interest (ROIs) were manually drawn on T1-weighted images (T1WI) along the boundary of the tumor, and radiomic features were extracted. Radiomic features related to survival prognosis were selected and used to construct a radiomics model. The patients were classified into two different risk stratifications according to the Risk-score calculated from the radiomics model. The log-rank test was used to test the difference in survival between the two stratifications to verify the classification value of the radiomics model. Clinical features related to the prognosis were used to construct a clinical model or clinical-radiomics model together with the radiomic features. Then, the clinical model, radiomics model, and clinical-radiomics model were compared to validate the improvement of radiomics in predicting the prognosis of medulloblastoma. The performance of the three models was evaluated with the C-index and the time-dependent AUC. Overall survival (OS) was defined as the time from receiving the operation to death or last follow-up.
A total of 81 children were included in this study. A total of five prognostic radiomic features were selected. The radiomics model could discriminate different risk hierarchies with good performance power in the training and testing datasets (training set = 0.0009; test set = 0.0286). Six clinical features associated with prognosis (duration of disease, risk hierarchy, dissemination, radiology, chemotherapy, and last postoperative white blood cell (WBC) level in CSF) were selected. The radiomic-clinical molecular features had better predictive value for OS (C-index = 0.860; Brier score: 0.087) than the radiomic features (C-index = 0.762; Brier score: 0.073) or clinical molecular characteristics (C-index = 0.806; Brier score: 0.092).
Radiomic features based on T1-weighted imaging have predictive value for pediatric medulloblastoma. Radiomics has incremental value in predicting the prognosis of MB, and clinical-radiomics models have a better predictive effect than clinical models.
髓母细胞瘤(MB)是儿科人群中最常见的颅内肿瘤,其五年生存率在60%至80%之间。在手术干预前预测儿童髓母细胞瘤的预后结果对于有效指导治疗方式至关重要。在各种肿瘤谱的预后预测和治疗管理中,放射组学已成为一种广泛应用的工具。本研究旨在建立基于放射组学的儿童MB预后预测模型,并验证放射组学特征与临床特征相结合时在预测MB预后中的作用。
将2012年12月至2022年3月在我院诊断为髓母细胞瘤的患者随机分为训练队列(n = 40)和测试队列(n = 41)。在T1加权图像(T1WI)上沿肿瘤边界手动绘制感兴趣区域(ROI),并提取放射组学特征。选择与生存预后相关的放射组学特征并用于构建放射组学模型。根据从放射组学模型计算出的风险评分将患者分为两种不同的风险分层。采用对数秩检验来检验两个分层之间的生存差异,以验证放射组学模型的分类价值。将与预后相关的临床特征与放射组学特征一起用于构建临床模型或临床-放射组学模型。然后,比较临床模型、放射组学模型和临床-放射组学模型,以验证放射组学在预测髓母细胞瘤预后方面的改善。用C指数和时间依赖性AUC评估这三种模型的性能。总生存期(OS)定义为从接受手术到死亡或最后一次随访的时间。
本研究共纳入81名儿童。共选择了五个预后放射组学特征。放射组学模型在训练和测试数据集中能够很好地区分不同的风险等级(训练集P = 0.0009;测试集P = 0.0286)。选择了六个与预后相关的临床特征(病程、风险等级、播散、放射学、化疗以及脑脊液中术后最后一次白细胞(WBC)水平)。与放射组学特征(C指数 = 0.762;Brier评分:0.073)或临床分子特征(C指数 = 0.806;Brier评分:0.092)相比,放射组学-临床分子特征对OS具有更好的预测价值(C指数 = 0.860;Brier评分:0.087)。
基于T1加权成像的放射组学特征对儿童髓母细胞瘤具有预测价值。放射组学在预测MB预后方面具有增量价值,且临床-放射组学模型比临床模型具有更好的预测效果。